TEP1

Across TCGA pan-cancer cohorts, TEP1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TEP1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher TEP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TEP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, UCEC, and PAAD are the cancer types where TEP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.883	0.431	.020	16	view →
PAAD	DFS	Median	All	0.006	0.505	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
KIRP	OS	Median	III,IV	0.236	0.809	<.001	12	view →
CESC	OS	Median	III,IV	0.232	0.668	.049	6	view →
SARC	DFS	Median	All	0.065	0.632	<.001	3	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TEP1–READ (OS)

Open the READ breakdown →